Elevance Health beat earnings estimates in Q4 2025, raised 2026 guidance, and saw rising institutional interest.

Elevance Health, formerly Anthem, reported strong Q4 earnings on January 28, 2026, with $3.33 EPS, beating estimates by $0.23, and revenue of $49.31 billion, up 9.6% year-over-year. The company raised its 2026 earnings guidance to $25.50 per share, announced a quarterly dividend of $1.72, and saw increased institutional interest, including a 46.7% stake rise by Hyperion Capital and a 97.9% increase by Gotham Asset Management. The stock, trading at $291.69 with a market cap of $64.38 billion, has a low beta of 0.51 and a 2.4% dividend yield, supported by a "Moderate Buy" analyst consensus and a $387.40 average price target.